Cancer Prevention Pharmaceuticals Completes Target Enrollment in Pivotal Phase 3 Clinical Trial Evaluating CPP-1X/sulindac in Patients with Familial Adenomatous Polyposis

Cancer Prevention Pharmaceuticals, Inc. (CPP), a private biotech company developing novel therapeutics to prevent cancer and other diseases, announced today that target enrollment has been achieved for the company’s pivotal Phase 3 clinical trial, CPP FAP-310, evaluating CPP-1X/sulindac in adults with familial adenomatous polyposis (FAP). FAP is a rare genetic disease that, if untreated, progresses to colorectal cancer in almost all cases. The trial has enrolled 166 patients at 21 research institutes in the United States, Canada and Europe.Continue reading

CDISC, C-Path and TransCelerate Announce Availability of New and Updated Standards for COPD, Virology and Diabetes

The Clinical Data Interchange Standards Consortium (CDISC), the Critical Path Institute (C-Path) and TransCelerate BioPharma, Inc. (“TransCelerate”) today announce the open availability of new and updated CDISC Therapeutic Area (TA) Standards in the areas of Chronic Obstructive Pulmonary Disease (COPD), Virology, and Diabetes.

Continue reading

Making LIFE Better: NYTimes chronicals the journey from the Jarvic 7 to the SynCardia Total Artificial Heart

Produced by Retro Report for The New York Times, A CHANGE OF HEART shows how  the modern-day SynCardia Total Artificial Heart has come full circle from its origins as a permanent heart to successfully pioneering use as a bridge to transplant to a new FDA clinical study for permanent use. Watch the documentary and hear what this life-saving and life-changing innovation means to the most important person…a patient.

Continue reading